Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology

Patent and Clinical Development - Anixa Biosciences collaborator, Cleveland Clinic, received a "Decision to Grant" notice from the Japan Patent Office for the patent application titled "Vaccine Adjuvants and Formulations" [1] - The Japanese patent extends the claims for the novel breast cancer vaccine technology to an additional geographic region, beyond the U.S. and European patents previously awarded [1] - The vaccine is currently being studied in a phase one clinical trial at Cleveland Clinic [1] Vaccine Technology - The breast cancer vaccine targets endogenously produced proteins, such as α-lactalbumin, which are no longer found post-lactation in normal, aging tissues but are present in certain breast cancers [2] - The vaccine activates the immune system against these "retired" proteins, providing preemptive immune protection against emerging breast tumors that express α-lactalbumin [2] - The vaccine contains an adjuvant that activates an innate immune response, enabling the immune system to mount a response against emerging tumors to prevent them from growing [2] Inventor and Licensing - The vaccine technology was invented by the late Dr. Vincent Tuohy, who held the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research at Cleveland Clinic's Lerner Research Institute [3] - Cleveland Clinic exclusively licensed this technology to Anixa Biosciences [3] - Dr. Tuohy was entitled to a portion of the commercialization revenues received by Cleveland Clinic and also held equity in Anixa [3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on the treatment and prevention of cancer [4] - The company's therapeutic portfolio includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, using chimeric endocrine receptor T-cell (CER-T) technology [4] - Anixa's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to prevent breast cancer, specifically triple negative breast cancer (TNBC), and ovarian cancer, as well as additional cancer vaccines targeting high incidence malignancies in lung, colon, and prostate [4] - The company's business model involves partnering with world-renowned research institutions for development and commercialization of emerging technologies [4]